Cargando…

Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target

BACKGROUND: Glioma is a primary malignancy of the central nervous system (CNS). As biomedicine advances, an efficient molecular target is urgently needed for the diagnosis and treatment of glioma. Meanwhile, several studies have demonstrated that glioma development is closely related to immunity. PA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Hao, Chai, Songshan, Wang, Yihao, Wang, Jiajing, Xiao, Dongdong, Li, Junjun, Xiong, Nanxiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366751/ https://www.ncbi.nlm.nih.gov/pubmed/32678519 http://dx.doi.org/10.1111/cns.13380

Ejemplares similares

Molecular and clinical features of a potential immunotherapy target ELK3 in glioma
por: Xu, Hao, et al.
Publicado: (2022)

Remodelling and Treatment of the Blood-Brain Barrier in Glioma
por: Wang, Yihao, et al.
Publicado: (2021)

CNN3 in glioma: The prognostic factor and a potential immunotherapeutic target
por: Xu, Hao, et al.
Publicado: (2021)

ELTD1 facilitates glioma proliferation, migration and invasion by activating JAK/STAT3/HIF-1α signaling axis
por: Li, Junjun, et al.
Publicado: (2019)

14‐3‐3ζ promotes gliomas cells invasion by regulating Snail through the PI3K/AKT signaling
por: Li, Junjun, et al.
Publicado: (2019)

Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges
por: Piper, Keenan, et al.
Publicado: (2021)

Hybrid surgery for coexistence of cerebral arteriovenous malformation and primitive trigeminal artery: A case report and literature review
por: Wang, Lesheng, et al.
Publicado: (2022)

Experiences and Expectations for Glioma Immunotherapeutic Approaches
por: Yamanaka, Ryuya, et al.
Publicado: (2014)

Current Immunotherapeutic Approaches for Malignant Gliomas
por: Han, Myung-Hoon, et al.
Publicado: (2022)

Pard3 suppresses glioma invasion by regulating RhoA through atypical protein kinase C/NF‐κB signaling
por: Li, Junjun, et al.
Publicado: (2019)

Novel prognostic features and personalized treatment strategies for mitochondria-related genes in glioma patients
por: Wu, Ji, et al.
Publicado: (2023)

Immunotherapeutic Potential of Extracellular Vesicles
por: Zhang, Bin, et al.
Publicado: (2014)

PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities
por: Sim, Hao-Wen, et al.
Publicado: (2022)

Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells
por: Wu, Shang-Ju, et al.
Publicado: (2023)

New Drug Updates in Solid Tumors: PARP Inhibitors in Ovarian Cancer, Immunotherapeutics, and Other Agents
por: Li, Edward
Publicado: (2018)

Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas
por: Wang, Yuxiang, et al.
Publicado: (2020)

A PARP1-related prognostic signature constructing and PARP-1 inhibitors screening for glioma
por: Li, Hui, et al.
Publicado: (2022)

The Consistency Between the Preoperative 3D-Reconstructed Meckel’s Cave and the Intraoperative Balloon Results in Percutaneous Balloon Compression
por: Cheng, Runqi, et al.
Publicado: (2023)

Machine learning screening for Parkinson’s disease-related cuproptosis-related typing development and validation and exploration of personalized drugs for cuproptosis genes
por: Wu, Ji, et al.
Publicado: (2023)

Metabolism-Relevant Molecular Classification Identifies Tumor Immune Microenvironment Characterization and Immunotherapeutic Effect in Cervical Cancer
por: Li, Luyi, et al.
Publicado: (2021)

The molecular feature of macrophages in tumor immune microenvironment of glioma patients
por: Zhang, Hao, et al.
Publicado: (2021)

Immunotherapeutic Targeting in Autoimmune Diseases
por: Janikashvili, Nona, et al.
Publicado: (2016)

A potential immunotherapeutic and prognostic biomarker for multiple tumors including glioma: SHOX2
por: Wu, Xiaocong, et al.
Publicado: (2023)

Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures
por: Zhang, Xinke, et al.
Publicado: (2021)

Dual Antigen T Cell Engagers Targeting CA9 as an Effective Immunotherapeutic Modality for Targeting CA9 in Solid Tumors
por: Tatari, Nazanin, et al.
Publicado: (2022)

Development and validation of a glioma-associated mesenchymal stem cell-related gene prognostic index for predicting prognosis and guiding individualized therapy in glioma
por: Peng, Zesheng, et al.
Publicado: (2023)

Molecular Basis of Acute Cystitis Reveals Susceptibility Genes and Immunotherapeutic Targets
por: Ambite, Ines, et al.
Publicado: (2016)

Against the Resilience of High-Grade Gliomas: The Immunotherapeutic Approach (Part I)
por: Giotta Lucifero, Alice, et al.
Publicado: (2021)

Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations
por: Aggarwal, Payal, et al.
Publicado: (2022)

9 A Proteomic Style Approach to Characterize a Grass Mix Product Reveals Potential Immunotherapeutic Benefit
por: Skinner, Murray, et al.
Publicado: (2012)

Macrophages as a Potential Immunotherapeutic Target in Solid Cancers
por: Mishra, Alok K., et al.
Publicado: (2022)

Immune microenvironment of medulloblastoma: The association between its molecular subgroups and potential targeted immunotherapeutic receptors
por: Kurdi, Maher, et al.
Publicado: (2023)

Molecular and clinical characterization of Galectin‐9 in glioma through 1,027 samples
por: Yuan, Feng, et al.
Publicado: (2019)

ANXA1: An Important Independent Prognostic Factor and Molecular Target in Glioma
por: Zhang, Dongdong, et al.
Publicado: (2022)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
por: Nadeem, Omar, et al.
Publicado: (2020)

Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target
por: Pierini, Stefano, et al.
Publicado: (2020)

Tumor Immune Microenvironment Landscape in Glioma Identifies a Prognostic and Immunotherapeutic Signature
por: Zhang, Chunyu, et al.
Publicado: (2021)

Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas
por: Wei, Cheng, et al.
Publicado: (2022)

Targeting Long Noncoding RNA in Glioma: A Pathway Perspective
por: Li, Junyang, et al.
Publicado: (2018)

Autologous bone fragments for skull reconstruction after microvascular decompression
por: Cai, Yuankun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4cmthgncve9obqhv3tvlqbadkd